

3G-17-21  
 17-21  
 3G-17-21(A21L)  
 17-21(A21L)  
 3G-1-40  
 3G-1-42  
 1-29  
 3G-1-29  
 10-25  
 3G-10-25  
 16-30  
 3G-16-30  
 Fc  
 Mock  
  
 Fc  
 1-40  
 1-42

Cells

Medium

**FIGURE 1**




FIGURE 2

BssHII-Spe-BamHI converter:

	<u>BssHII</u>		<u>SpeI</u>	<u>BamHI</u>					
DI215	CGCGCTTCAGAAGAACTAGTG								
			GAAGTCTTCTTGATCACCTAG		DI216				
	A	R	F	R	R	T	S	A	S

FIGURE 3




FIGURE 4



FIGURE 5

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
D	A	E	F	R	H	D	S	G	Y	E	V	H	H	Q	K	L	V	F	F	A
GACGCAGAATTCCGTCATGACTCCGGATACGAAGTGCACCACCAAAAGCTTGTATTCTTCGCA																				
EcoRI				BspHI				BspEI				ApaLI				HindIII				
22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42
E	D	V	G	S	N	K	G	A	I	I	G	L	M	V	G	G	V	V	I	A
GAAGACGTCGGATCCAACAAAGGTGCCATAATAGGCCTTATGGTAGGTGGAGTAGTGATAGCA																				
AatII						BamHI						StuI								

**FIGURE 6**

[illegible]

- **Overlapping complimentary oligonucleotides for pentapeptides:**

DI223 5' CGCGCTTCAGAAGAGGCGGTGGTCTTGTATTCTTCGCAA  
GAAGTCTTCTCCGCCACCAGAACATAAGAAGCGTTGATC DI224  
BssHII SpeI 5'

DI225 CGCGCTTCAGAAGACTTGTATTCTTCGCAA  
GAAGTCTTCTGAACATAAGAAGCGTTGATC DI226

DI227 CGCGCTTCAGAAGAGGCGGTGGTCTTGTATTCTTCCTTA  
GAAGTCTTCTCCGCCACCAGAACATAAGAAGGAATGATC DI228

**FIGURE 7A**

LVFFL:

DI229        CGCGCTTCAGAAGACTTGTATTCTTCCTTA  
              GAAGTCTTCTGAACATAAGAAGGAATGATC DI230

- PCR primers for longer fragments

$\beta$ -amyloid 1-29 oligos

For 5' use oligos 217 and 217-3G

DI-231        TGGACTAGTACCTTTGTTGGATCCGAC

$\beta$ -amyloid 10-25 oligos

DI-232        TTAGCGCGCTTCAGAAGATACGAAGTGCACCACCAA

DI-232-3G  
              TTAGCGCGCTTCAGAAGAGGCGGTGGTTACGAAGTGCACCACCAA

DI-233        TGGACTAGTTCCGACGTCTTCTGCGAA


$\beta$ -amyloid 16-30 oligos

DI-234        TTAGCGCGCTTCAGAAGAAAGCTTGTATTCTTCGCA

DI-234-3G  
              TTAGCGCGCTTCAGAAGAGGCGGTGGTAAGCTTGTATTCTTCGCA

DI-235        TGGACTAGTGGCACCTTTGTTGGATCC

**FIGURE 7B**



**FIGURE 8**



[<sup>125</sup>I] amyloid  
binding to fibrils





FIGURE 9



**FIGURE10**

ATGGATGCAATGAAGAGAGGGCTCTGCTGTGTGCTGCTGCTGTGTGGAGC  
AGTCTTCGTAAAGCTTGTATTCTTCGCAGAAGACGTCGGATCGAACAAAG  
GTGCCGAGCCCAAATCTTGTGACAAAACCTCACACATGCCCACCGTGCCCA  
GCACCTGAACTCCTGGGGGGGACCGTCAGTCTTCCTCTTCCCCCAAACCC  
AAGGACACCCTCATGATATCCCGGACCCCTGAGGTCACATGCGTGGTGGT  
GGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACG  
GCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAA  
CAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGC  
TGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCC  
CCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCAC  
AGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTC  
AGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGA  
GTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCC  
GTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGAC  
AAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGA  
GGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTA  
AATGA

**FIGURE 11**

tPA → 16-30 beta amyloid → human Fc →

MDAMKRGLCCVLLLCGAVFVKLVFFAEDVGSNKGAEPKSCDKTHTCPPCPAPE

LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA

KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG

QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSVSMHEALHNHYTQKSLSLSPGK.

**FIGURE 12**